<DOC>
	<DOC>NCT00124215</DOC>
	<brief_summary>The GI-5005 therapeutic vaccine or placebo will be injected under the skin of hepatitis C virus (HCV) subjects. Patients will be monitored for safety, immune responses and any therapeutic benefits related to the injections.</brief_summary>
	<brief_title>Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>Patients with chronic hepatitis C virus infection including treatment naive subjects as well as subjects who are partial responders and relapsers to prior interferon therapy &gt;18 years of age Negative skin test for hypersensitivity to saccharomyces cerevisiae. Nonresponders to previous interferon treatments Cirrhosis HCV treatment within 3 months Hepatitis B infection HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>HCV</keyword>
	<keyword>vaccine</keyword>
	<keyword>Hepatitis C Infection</keyword>
</DOC>